

## Neurotech receives \$4.73m R&D tax incentive refund

**Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company")**, a clinical-stage biopharmaceutical company focused on paediatric neurological disorders, is pleased to announce that it has received a research and development (R&D) tax incentive refund for the financial year ended 30 June 2025 for a total of \$4.73m.

The refund is received as part of the Australian Government's R&D tax incentive, which provides companies engaging in appropriate and eligible activities with a refundable tax offset of up to 48.5%.

Neurotech will utilise the funds for further clinical development of its pipeline aimed at the treatment of paediatric neurological disorders and working capital.

### Authority

This announcement has been authorised for release by the Managing Director of Neurotech International Limited.

For further information contact us via [info@neurotechinternational.com](mailto:info@neurotechinternational.com)

### About Neurotech

**Neurotech International Limited (ASX:NTI)** is a clinical-stage biopharmaceutical development company focused predominantly on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.